Business And Significant Accounting Policies, Narratives (Details) $ in Thousands	3 Months Ended
	Mar. 31, 2020 USD ($) product	Dec. 31, 2019 USD ($)
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of product candidate in active clinical development | product	1
Retained Earnings (Accumulated Deficit)	$ (917,221)	$ (912,008)
Cash and money market funds, amortized cost	32,854	32,649
Long-term Debt	240,732	241,727
Convertible Notes
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Long-term Debt	$ 181,822	$ 183,006
Qsymia, PANCREASE/PANCREASE MT, STENDRA/SPEDRA member
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Number of Approved Federal Drug Administration Therapies | product	3